Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

Charlotte Lund Denholt; Tina Binderup; Marie-Thérése Stockhausen; Hans Skovgaard Poulsen; Mogens Spang-Thomsen; Paul Robert Hansen; Nic Gillings; Andreas Kjær

doi:10.1016/j.nucmedbio.2010.11.003

Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

Charlotte Lund Denholt, Tina Binderup, Marie-Thérése Stockhausen, Hans Skovgaard Poulsen, Mogens Spang-Thomsen, Paul Robert Hansen, Nic Gillings, Andreas Kjær

Department of Clinical Physiology and Nuclear Medicine

19 Citations (Scopus)

Abstract

This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[(18)F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2,) ([(18)F]FBA-FALGEA-NH(2)) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth factor receptor (EGFR) variant III mutation, EGFRvIII.

Original language	English
Journal	Nuclear Medicine and Biology
Volume	38
Issue number	4
Pages (from-to)	509-15
Number of pages	7
ISSN	0969-8051
DOIs	https://doi.org/10.1016/j.nucmedbio.2010.11.003
Publication status	Published - May 2011

Access to Document

10.1016/j.nucmedbio.2010.11.003

Cite this

Denholt, C. L., Binderup, T., Stockhausen, M.-T., Poulsen, H. S., Spang-Thomsen, M., Hansen, P. R., Gillings, N., & Kjær, A. (2011). Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology, 38(4), 509-15. https://doi.org/10.1016/j.nucmedbio.2010.11.003

Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. / Denholt, Charlotte Lund; Binderup, Tina; Stockhausen, Marie-Thérése et al.
In: Nuclear Medicine and Biology, Vol. 38, No. 4, 05.2011, p. 509-15.

Research output: Contribution to journal › Journal article › Research › peer-review

Denholt, CL, Binderup, T, Stockhausen, M-T, Poulsen, HS, Spang-Thomsen, M, Hansen, PR, Gillings, N & Kjær, A 2011, 'Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer', Nuclear Medicine and Biology, vol. 38, no. 4, pp. 509-15. https://doi.org/10.1016/j.nucmedbio.2010.11.003

@article{8a626903651649aa9f5a5d2da016f7d2,

title = "Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer",

abstract = "This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[(18)F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2,) ([(18)F]FBA-FALGEA-NH(2)) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth factor receptor (EGFR) variant III mutation, EGFRvIII.",

author = "Denholt, \{Charlotte Lund\} and Tina Binderup and Marie-Th{\'e}r{\'e}se Stockhausen and Poulsen, \{Hans Skovgaard\} and Mogens Spang-Thomsen and Hansen, \{Paul Robert\} and Nic Gillings and Andreas Kj{\ae}r",

year = "2011",

month = may,

doi = "10.1016/j.nucmedbio.2010.11.003",

language = "English",

volume = "38",

pages = "509--15",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

AU - Denholt, Charlotte Lund

AU - Binderup, Tina

AU - Stockhausen, Marie-Thérése

AU - Poulsen, Hans Skovgaard

AU - Spang-Thomsen, Mogens

AU - Hansen, Paul Robert

AU - Gillings, Nic

AU - Kjær, Andreas

PY - 2011/5

Y1 - 2011/5

N2 - This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[(18)F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2,) ([(18)F]FBA-FALGEA-NH(2)) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth factor receptor (EGFR) variant III mutation, EGFRvIII.

AB - This study describes the radiosynthesis, in vitro and in vivo evaluation of the novel small peptide radioligand, 4-[(18)F]fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2,) ([(18)F]FBA-FALGEA-NH(2)) as a positron emission tomography (PET) tracer for imaging of the cancer specific epidermal growth factor receptor (EGFR) variant III mutation, EGFRvIII.

UR - https://www.scopus.com/pages/publications/79955467043

U2 - 10.1016/j.nucmedbio.2010.11.003

DO - 10.1016/j.nucmedbio.2010.11.003

M3 - Journal article

C2 - 21531288

SN - 0969-8051

VL - 38

SP - 509

EP - 515

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 4

ER -

Evaluation of 4-[(18)F]fluorobenzoyl-FALGEA-NH(2) as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this